0001390478-26-000003
SEC filingSELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company, reported a net loss of $26.9 million for FY 2025, an improvement from $30.9 million in FY 2024, driven by reduced research and development expenses of $16.0 million (down from $19.1 million) and stable general and administrative costs at $12.3 million. Total operating expenses were $28.3 million, resulting in a loss from operations of $28.3 million, partially offset by $1.4 million in interest income. No revenue was generated, consistent with its pre-commercial stage focused on GPS and SLS009 product candidates. Balance sheet strengthened significantly with cash and cash equivalents rising to $71.8 million from $13.9 million, supported by $86.3 million in net financing inflows from warrant inducements ($51.0 million), equity issuances ($23.1 million), and warrant exercises ($12.6 million). Total assets reached $78.3 million, with stockholders' equity at $70.9 million. Operating cash use was $28.4 million, but net cash increase was $57.9 million. The company believes its cash position funds operations for at least 12 months, amid ongoing Phase 3 REGAL trial for GPS in AML maintenance, with 72 events reached as of late 2025. Arbitration with 3D Medicines continues over milestones.
SELLAS reported FY2025 net loss of $26.9M, better than $30.9M in FY2024, due to R&D expense decline to $16.0M from $19.1M while G&A held at $12.3M vs $12.4M. Operating loss $28.3M improved from $31.5M, aided by $1.4M interest income (up from $0.6M). No revenue as clinical-stage biotech. Shares basic/diluted 109.1M vs 61.2M prior, reflecting financings. Cash position bolstered to $71.8M from $13.9M via $86.3M financing cash.
No revenue recognized in FY2025 or FY2024. Company pre-revenue, focused on GPS (Phase 3 REGAL trial ongoing, 72 events by Dec 2025) and SLS009. Potential milestones from 3D Medicines ($191.5M remaining) constrained; arbitration ongoing over payments.
N/A - pre-revenue. Operating loss margin effectively -100% on zero revenue. Expenses controlled: R&D down 16%, G&A flat. Stock-based comp $2.0M.
Ops cash use $28.4M (vs $35.4M prior). Financing $86.3M from warrant inducements $51.0M, issuances $23.1M, exercises $12.6M. Net cash increase $57.9M. BS: Assets $78.3M (cash 92%), liabilities $7.5M, equity $70.9M (accum deficit -$275.0M). Shares issued/outstanding 153.1M.
Cash sufficient for 12+ months post-year-end (incl $42.6M post-period exercises). REGAL trial event-driven final analysis at 80 events; IDMC recommended continuation. SLS009 advancing. Risks: trial outcomes, funding needs, 3D Medicines arbitration, competition in AML/CDK9 space.